drugset / Trial / NCT05326152

Intralesional Versus Intramuscular Hepatitis B Vaccine Immunotherapy for Warts

NCT05326152

Phase 1/2 Completed 75 enrolled Zagazig University
RandomizedParallel-groupSingle-blindTreatment

Summary

Assessment of the effectiveness of intralesional and intramuscular hepatitis B vaccine in treatment of multiple common warts.

Timeline

Start
2020-11-25
Primary completion
2021-06-20
Completion
2021-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Hepatitis B vaccine Vaccine 0.2 ml Intramuscular
Subject Hepatitis B vaccine Vaccine 0.5 ml Intramuscular
Subject Hepatitis B vaccine Vaccine 1 ml Intramuscular

Indications

No indication recorded.